Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
DURECT Corporation focuses on developing innovative therapeutics for chronic diseases, particularly in the areas of pain management and liver disease. Its proprietary drug delivery technologies, such as the DUR-928 compound, provide unique advantages in efficacy and safety profiles, differentiating it from competitors in the specialty pharmaceuticals market.
DURECT primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies, leveraging its proprietary drug delivery technologies. The company has a strong pipeline, particularly with DUR-928, which targets unmet medical needs, allowing for potential pricing power and competitive advantages in niche markets.
Clinical trial results for DUR-928 and other pipeline candidates
Partnership announcements or licensing deals with larger pharmaceutical companies
Regulatory approvals from the FDA for new drug applications
Market adoption rates for any approved therapeutics
Regulatory changes that could impact drug approval processes
Technological disruption in drug delivery systems
Emergence of alternative therapies for chronic pain and liver disease
Increased competition from larger pharmaceutical firms with more resources
Negative cash flow impacting liquidity and operational sustainability
Potential dilution of shares if additional capital is raised through equity financing
low - DURECT operates in a niche pharmaceutical market that is less sensitive to economic cycles, as demand for healthcare products tends to be more stable.
Minimal impact; however, rising interest rates could increase the cost of capital for R&D financing, potentially affecting future projects.
minimal - The company has a manageable debt-to-equity ratio of 0.44, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in biotech and pharmaceuticals.
high - The stock has shown significant volatility, with a 3-month return of 205.3% reflecting speculative trading.
